ADC Therapeutics SA (ADCT)

USD 1.44

(0.7%)

Net Debt Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual net debt in 2023 was -154.22 Million USD , up 26.23% from previous year.
ADC Therapeutics SA's latest quarterly net debt in 2024 Q2 was -175.72 Million USD , down -59.81% from previous quarter.
ADC Therapeutics SA reported annual net debt of -209.06 Million USD in 2022, up 42.69% from previous year.
ADC Therapeutics SA reported annual net debt of -364.79 Million USD in 2021, up 8.19% from previous year.
ADC Therapeutics SA reported quarterly net debt of -175.72 Million USD for 2024 Q2, down -59.81% from previous quarter.
ADC Therapeutics SA reported quarterly net debt of -186.87 Million USD for 2023 Q3, up 16.53% from previous quarter.

Annual Net Debt Chart of ADC Therapeutics SA (2023 - 2016)

Historical Annual Net Debt of ADC Therapeutics SA (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	-154.22 Million USD	26.23%
2022	-209.06 Million USD	42.69%
2021	-364.79 Million USD	8.19%
2020	-397.32 Million USD	-259.5%
2019	-110.52 Million USD	20.38%
2018	-138.8 Million USD	47.17%
2017	-262.75 Million USD	-82.89%
2016	-143.66 Million USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-109.95 Million USD	28.7%
2024 Q2	-175.72 Million USD	-59.81%
2023 Q3	-186.87 Million USD	16.53%
2023 Q1	-187.6 Million USD	10.27%
2023 FY	-154.22 Million USD	26.23%
2023 Q4	-154.22 Million USD	17.48%
2023 Q2	-223.89 Million USD	-19.35%
2022 Q1	-328.31 Million USD	10.0%
2022 FY	-209.06 Million USD	42.69%
2022 Q4	-209.06 Million USD	20.87%
2022 Q3	-264.2 Million USD	3.39%
2022 Q2	-273.46 Million USD	16.71%
2021 Q2	-272.44 Million USD	18.75%
2021 Q3	-429.54 Million USD	-57.66%
2021 Q4	-364.79 Million USD	15.07%
2021 FY	-364.79 Million USD	8.19%
2021 Q1	-335.32 Million USD	15.6%
2020 Q2	-308.19 Million USD	-366.72%
2020 Q3	-454.33 Million USD	-47.42%
2020 Q1	115.55 Million USD	204.55%
2020 FY	-397.32 Million USD	-259.5%
2020 Q4	-397.32 Million USD	12.55%
2019 Q2	-176.78 Million USD	-227.36%
2019 Q4	-110.52 Million USD	0.0%
2019 FY	-110.52 Million USD	20.38%
2019 Q1	138.8 Million USD	200.0%
2018 Q1	262.75 Million USD	0.0%
2018 Q3	-138.8 Million USD	0.0%
2018 Q4	-138.8 Million USD	0.0%
2018 FY	-138.8 Million USD	47.17%
2017 FY	-262.75 Million USD	-82.89%
2016 FY	-143.66 Million USD	0.0%

Peer Net Debt Comparison of ADC Therapeutics SA

Name	Net Debt	Net Debt Difference
Alto Neuroscience, Inc.	68.91 Million USD	323.784%
Annovis Bio, Inc.	-5.75 Million USD	-2579.904%
Biohaven Pharmaceutical Holding Company Ltd.	-218.84 Million USD	29.529%
Ginkgo Bioworks Holdings, Inc.	-707.09 Million USD	78.189%
Nuvation Bio Inc.	-38.64 Million USD	-299.102%
Nuvation Bio Inc.	-38.64 Million USD	-299.102%
Arcus Biosciences, Inc.	-116 Million USD	-32.949%
Zymeworks Inc.	-130.83 Million USD	-17.874%